Fresh off a $10 million funding round, M3 Biotechnology is preparing for clinical trials for its Alzheimer’s drug. The Seattle company plans to begin conducting human safety trials for the treatment by the end of this year.
CEO Leen Kawas said Wednesday that $8 million of the newly raised round will go toward prepping for trials and speeding up the development of drugs in its pipeline. The remaining $2 million will be used to run a Phase 1 clinical trial that will test the safety of the drug in…Fresh off a $10 million funding round, M3 Biotechnology is preparing for clinical trials for its Alzheimer’s drug. The Seattle company plans to begin conducting human safety trials for the treatment by the end of this year.
CEO Leen Kawas said Wednesday that $8 million of the newly raised round will go toward prepping for trials and speeding up the development of drugs in its pipeline. The remaining $2 million will be used to run a Phase 1 clinical trial that will test the safety of the drug in…